|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10471048104910501051105210531054105510561057...10631064» |
- dovitinib (TKI258) / Novartis, Oncoheroes
New P1 trial, Combination therapy: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 5, 2012
P1, N=0, Withdrawn, Sponsor: University of Florida
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting
- ||| Omnaris (ciclesonide nasal spray) / Covis Pharma, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change: Omnaris Versus Levocetirizine Phase 4 Study (clinicaltrials.gov) - Sep 4, 2012
P4, N=349, Completed, Sponsor: Handok Pharmaceuticals Co., Ltd.
Recruiting --> Active, not recruiting N=237 --> 349
- |||| Omnaris (ciclesonide nasal spray) / Covis Pharma, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: Omnaris Versus Levocetirizine Phase 4 Study (clinicaltrials.gov) - Sep 4, 2012
P4, N=349, Completed, Sponsor: Handok Pharmaceuticals Co., Ltd.
N=237 --> 349 Recruiting --> Completed
- dexamethasone / Generic mfg.
Enrollment change: FST-201 In The Treatment of Acute Fungal Otitis Externa (clinicaltrials.gov) - Sep 4, 2012
P3, N=6, Terminated, Sponsor: Foresight Biotherapeutics
Recruiting --> Completed N=120 --> 6
- triamcinolone acetonide topical / Generic mfg.
Enrollment change: NdYag Laser for Acne Keloidalis Nuchae (clinicaltrials.gov) - Sep 3, 2012
P=N/A, N=20, Active, not recruiting, Sponsor: Henry Ford Health System
N=120 --> 6 N=30 --> 20
- || paracetamol / Generic mfg.
New P3 trial: ANPATHY: Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia. (clinicaltrials.gov) - Sep 3, 2012
P3, N=66, Completed, Sponsor: University Hospital, Lille
- ||||||| budesonide/formoterol / Generic mfg.
Trial completion: New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day (clinicaltrials.gov) - Sep 2, 2012
P3, N=214, Completed, Sponsor: AstraZeneca
N=30 --> 20 Active, not recruiting --> Completed
- || Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change: SISRIP: Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis (clinicaltrials.gov) - Aug 30, 2012
P=N/A, N=1630, Completed, Sponsor: Takeda
Active, not recruiting --> Completed N=2400 --> 1630
- Enrollment open, Surgery: Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery (clinicaltrials.gov) - Aug 30, 2012
P=N/A, N=100, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=2400 --> 1630 Not yet recruiting --> Recruiting
- ||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: SISRIP: Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis (clinicaltrials.gov) - Aug 30, 2012
P=N/A, N=1630, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- || Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial: A Fluticasone Furoate/Vilanterol 12-Week Study to test lung function in people with Chronic Bronchitis and/or Emphysema (EUDRACT) - Aug 30, 2012
P3, N=130, Ongoing, Sponsor: GlaxoSmithKline Research & Development Limited
- ||||| dexamethasone / Generic mfg., carfilzomib / Generic mfg.
Combination therapy: CHAMPION 1: A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (clinicaltrials.gov) - Aug 30, 2012
P1/2, N=160, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- | Oxis Turbuhaler (formoterol) / AstraZeneca, Oxeze Turbuhaler (formoterol dry-powder inhaler) / AstraZeneca
Trial completion, MRI: Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler (clinicaltrials.gov) - Aug 30, 2012
P0, N=34, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Completed Recruiting --> Completed
- | dexamethasone injection / Generic mfg.
Trial initiation date: ACT: Trial of the Use of Antenatal Corticosteroids in Developing Countries (clinicaltrials.gov) - Aug 29, 2012
P3, N=6000, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed Initiation date: Mar 2011 --> Oct 2011
- | dexamethasone injection / Generic mfg.
Enrollment open: ACT: Trial of the Use of Antenatal Corticosteroids in Developing Countries (clinicaltrials.gov) - Aug 29, 2012
P3, N=6000, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Initiation date: Mar 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- | Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study (clinicaltrials.gov) - Aug 29, 2012
P2, N=26, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| abiraterone acetate / Generic mfg.
Enrollment change: A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=54, Completed, Sponsor: Cougar Biotechnology, Inc.
Active, not recruiting --> Completed N=44 --> 54
- | Darzalex (daratumumab) / J&J
Enrollment open, Combination therapy: Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=50, Recruiting, Sponsor: Genmab
N=44 --> 54 Not yet recruiting --> Recruiting
- |||| abiraterone acetate / Generic mfg.
Trial completion: A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=54, Completed, Sponsor: Cougar Biotechnology, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Nasonex (mometasone furoate nasal spray) / Merck (MSD)
New P3 trial: A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Aug 26, 2012
P3, N=1220, Completed, Sponsor: Perrigo Company
- || Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol Combination and Fluticasone Furoate in Adult and Adolescent Asthmatics (EUDRACT) - Aug 26, 2012
P3, N=60, Ongoing, Sponsor: GlaxoSmithKline Research and Development Limited
- ||||| budesonide/formoterol / Generic mfg.
Enrollment change: An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma (clinicaltrials.gov) - Aug 23, 2012
P3, N=558, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=240 --> 558
- | Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Decadron (dexamethasone) / Merck (MSD), Metopirone (metyrapone) / HRA Pharma
Biomarker, New P4 trial: Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures (clinicaltrials.gov) - Aug 23, 2012
P4, N=350, Recruiting, Sponsor: University of Michigan
- | linsitinib (ASP7487) / Sling Therap
New P1/2 trial, Combination therapy: A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 23, 2012
P1/2, N=75, Recruiting, Sponsor: University Health Network, Toronto
- Nasonex (mometasone furoate nasal spray) / Merck (MSD)
New P3 trial: Nasonex OSA: Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy (clinicaltrials.gov) - Aug 22, 2012
P3, N=50, Not yet recruiting, Sponsor: Children's & Women's Health Centre of British Columbia
- | Trial completion: Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 22, 2012
P2, N=40, Completed, Sponsor: Oncotherapeutics
N=240 --> 558 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Combination therapy: The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Aug 21, 2012
P3, N=200, Active, not recruiting, Sponsor: Copenhagen University Hospital at Herlev
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment closed: STAN: Study of Asthma and Nasal Steroids (clinicaltrials.gov) - Aug 20, 2012
P4, N=380, Active, not recruiting, Sponsor: American Lung Association Asthma Clinical Research Centers
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice (clinicaltrials.gov) - Aug 20, 2012
P=N/A, N=274, Completed, Sponsor: Handok Pharmaceuticals Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- AL101 / Ayala Pharma
Enrollment change: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 20, 2012
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed N=30 --> 42
- Decadron (dexamethasone) / Merck (MSD)
New P2 trial: Dexamethasone Dyspnea Study (clinicaltrials.gov) - Aug 19, 2012
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Tasigna (nilotinib) / Novartis, Inhibikase
New P2 trial: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 19, 2012
P2, N=44, Recruiting, Sponsor: Mayo Clinic
- | Empliciti (elotuzumab) / AbbVie, BMS
New P1/2 trial: SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov) - Aug 16, 2012
P1/2, N=122, Recruiting, Sponsor: Southwest Oncology Group
- | Veramyst (fluticasone furoate nasal spray) / GSK
New P1 trial: A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI) (clinicaltrials.gov) - Aug 16, 2012
P1, N=36, Completed, Sponsor: GlaxoSmithKline
- Enrollment closed: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 16, 2012
P1/2, N=31, Active, not recruiting, Sponsor: University of Washington
N=30 --> 42 Terminated --> Active, not recruiting
- ||||||| mapracorat (BOL-303242-X) / Bayer
Trial completion, Surgery: Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery (clinicaltrials.gov) - Aug 16, 2012
P3, N=250, Completed, Sponsor: Bausch & Lomb Incorporated
Terminated --> Active, not recruiting Active, not recruiting --> Completed
- | Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
New P1 trial: REFLI: Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (clinicaltrials.gov) - Aug 15, 2012
P1, N=48, Completed, Sponsor: Orion Corporation, Orion Pharma
- Decadron (dexamethasone) / Merck (MSD)
Trial completion, FDG PET: Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules (clinicaltrials.gov) - Aug 14, 2012
P1, N=9, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
Enrollment change: ESTHER: Symbicort Rapihaler Therapeutic Equivalence Study (clinicaltrials.gov) - Aug 13, 2012
P3, N=742, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=600 --> 742
- hydrocortisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial completion, Surgery: Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery (clinicaltrials.gov) - Aug 13, 2012
P=N/A, N=121, Completed, Sponsor: Cedars-Sinai Medical Center
N=600 --> 742 Recruiting --> Completed
- | Darzalex IV (daratumumab) / J&J
Clinical: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2012
P1/2, N=92, Recruiting, Sponsor: University of Chicago
- methylprednisolone sodium succinate / Generic mfg.
Enrollment open: Optic Neuritis Recovery After Oral or IV Corticosteroids (clinicaltrials.gov) - Aug 12, 2012
P2/3, N=46, Recruiting, Sponsor: London Health Sciences Centre
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| rocilinostat (ACY-1215) / Regenacy
Enrollment open, Combination therapy: Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=148, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| dexamethasone / Generic mfg., melphalan / Generic mfg.
Enrollment closed: Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Aug 12, 2012
P3, N=152, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| dasatinib / Generic mfg.
Enrollment closed: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Aug 12, 2012
P2, N=115, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Zevalin (ibritumomab tiuxetan) / Spectrum Pharma, Servier, Mundipharma
Clinical: ESHAP: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL (clinicaltrials.gov) - Aug 9, 2012
P2, N=52, Recruiting, Sponsor: University of Arizona
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||| apatorsen (OGX-427) / Achieve Life Sciences
Enrollment closed, Metastases: OGX-427 in Castration Resistant Prostate Cancer Patients (clinicaltrials.gov) - Aug 9, 2012
P2, N=72, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment change: Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma (clinicaltrials.gov) - Aug 8, 2012
P3, N=1667, Completed, Sponsor: Mundipharma Research Limited
Recruiting --> Active, not recruiting N=508 --> 1667
- |||| Serevent Diskhaler (salmeterol dry-powder inhaler) / GSK
Trial completion: Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study (clinicaltrials.gov) - Aug 8, 2012
P4, N=639, Completed, Sponsor: GlaxoSmithKline
N=508 --> 1667 Active, not recruiting --> Completed